Dr. Anthony Mato on the Difference Between Intolerance and Resistance in CLL
Anthony Mato, MD, MSCE, director of the CLL Program, University of Pennsylvania, discusses the difference between intolerance and resistance when giving patients with chronic lymphotic leukemia ibrutinib.
Anthony Mato, MD, MSCE, director of the Chronic Lymphotic Leukemia (CLL) Program, University of Pennsylvania, discusses the difference between intolerance and resistance when giving patients with CLL ibrutinib. Mato says when it comes to resistance, medical professionals should be wary of certain mutations occurring that disallow ibrutinib to bind to targets such as BTK. Mato adds that patients showing resistance to idelalisib is unclear is currently under investigation as to reasons why.
Mato adds that there is no clinical model to predict resistance at this juncture. He says the concept of resistance is too complex to be able to predict.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
